Shibuya-ku, Tokyo, Japan, Japan, May 17, 2021, 09:47 /Comserve / -- Companies Covered Major players covered—Novartis (Switzerland), AbbVie (US), Bristol-Myers Squibb (US), F. Hoffmann-La Roche (Switzerland), Sanofi (France), Pfizer (US), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (Japan)
The study involved four major activities in estimating the current size of the leukemia therapeutics market. Exhaustive secondary research was done to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.
With COVID-19 resulting in the economic fallout, numerous economies are working on game-changing improvements to protect their employees and clients. While focusing on the ongoing challenges, the leaders are embracing new plans in order to manage and stay afloat in this competitive environment.
Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-106804
"The Final Report will cover the impact analysis of COVID-19 on this industry (Global And Regional Market)."
Companies Covered Major 10 players covered—
Novartis (Switzerland),
AbbVie (US),
Bristol-Myers Squibb (US),
F. Hoffmann-La Roche (Switzerland),
Sanofi (France),
Pfizer (US),
Amgen (US),
Gilead Sciences (US),
Takeda Pharmaceutical (Japan), and
Celgene (US)
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the leukemia therapeutics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
The key players in the industry and markets have been identified through extensive secondary research
The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
This detailed analysis includes market size and forecasts, covering regional analysis, trends, opportunities and COVID-19 analysis. The analysis also includes key players with business strategies and key indicators that influence market growth.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.
Primary Research
Several stakeholders such as leukemia drug manufacturers, vendors, distributors and scientists, researchers, oncologist, and doctors from hospitals and clinics were consulted for this report. The demand side of this market is characterized by the significant use of immunotherapies and targeted drugs for leukemia treatment owing to the increasing incidence rate of leukemia across the globe. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
BREAKDOWN OF PRIMARY PARTICIPANTS:
Note 1: C-level primaries include chief executive officers (CEOs), chief operation officers (COOs), and chief financial officers (CFOs). D-level primaries include directors, managers, and heads of departments. Others include sales managers, marketing managers, and product managers.
Note 2: Company tiers are defined by their total revenues. As of 2017, Tier 1: >USD 1 billion; Tier 2: USD 50 million to USD 1 billion; and Tier 3: <50 million.
“To know about the assumptions considered for the study, download the pdf brochure.”
Data Triangulation
After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the leukemia industry.
Report Objectives
To define, describe, and forecast the leukemia therapeutics market on the basis of type, application, and region
To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, and opportunities)
To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukemia therapeutics market
To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
To forecast the size of the market segments in four geographical regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
To track and analyze competitive developments such as product launches, partnerships, expansions, and acquisitions in the leukemia therapeutics market
Scope of the Report
Report Metric Details
Market Size Available for Years 2017–2024
Base Year Considered 2018
Forecast Period 2019–2024
Forecast Units Value (USD)
Segments Covered Leukemia therapeutics market by treatment type, type of leukemia, gender, molecule type, mode of administration, and region
Geographies Covered North America (US, Canada), Europe (Germany, France, UK, and the RoE), APAC (Japan, China, Australia, and the RoAPAC), and the RoW
This research report categorizes the leukemia therapeutics market into the following segments and subsegments:
LEUKEMIA THERAPEUTICS MARKET, BY TYPE OF LEUKEMIA
Acute lymphocytic leukemia (ALL)
Chronic lymphocytic leukemia (CLL)
Acute myeloid leukemia (AML)
Chronic myeloid leukemia (CML)
LEUKEMIA THERAPEUTICS MARKET, BY TREATMENT TYPE
Targeted drugs & immunotherapy
Chemotherapy
LEUKEMIA THERAPEUTICS MARKET, BY MOLECULE TYPE
Small Molecules
Biologics
LEUKEMIA THERAPEUTICS MARKET, BY MODE OF ADMINISTRATION
Injectable
Oral
LEUKEMIA THERAPEUTICS MARKET, BY GENDER
Male
Female
LEUKEMIA THERAPEUTICS MARKET, BY REGION
North America
US
Canada
Europe
Germany
UK
France
Rest of Europe
Asia Pacific
China
Japan
India
Rest of Asia Pacific
Rest of the World
The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.
For more information, please contact:
Lauren BrownShibuya Data Count
Email: sales@sdki.jp
Tel: + 81 50 50509159
Related Links
https://www.sdki.us/